-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

295 Clonal Hematopoiesis Is Associated with Therapy-Related Myeloid Malignancies in the ElderlyClinically Relevant Abstract

Myelodysplastic Syndromes—Clinical Studies
Program: Oral and Poster Abstracts
Type: Oral
Session: 637. Myelodysplastic Syndromes—Clinical Studies: Predisposition and Diagnosis of Myelodysplastic Syndromes
Sunday, December 4, 2016: 7:30 AM
Grand Hall C (Manchester Grand Hyatt San Diego)

Nancy K Gillis, PharmD1,2,3*, Markus Ball, PhD4*, Qing Zhang, MD4*, YuLong Zhao, PhD4*, Sean Yoder, M.S5*, Maria E. Balasis6*, Tania E. Mesa7*, David Sallman, MD4, Jeffrey E. Lancet, MD4, Rami S. Komrokji, MD4, Alan F List, MD8, Howard L McLeod, PharmD1,2*, Dana E Rollison, PhD9 and Eric Padron, MD10

1DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center, Tampa, FL
2Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, FL
3Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC
4Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
5Molecular Genomics Core Facility, Moffit Cancer Center and Research Institute, Tampa, FL
6Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
7Molecular Genomics Core, H. Lee Moffitt Cancer Center, Tampa, FL
8Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
9Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL
10Division of Hematologic Malignancies, Moffitt Cancer Center, Tampa, FL


Clonal hematopoiesis of indeterminate potential (CHIP) is an age-dependent genetic event occurring in as high as 10% of individuals over age 70. Although the clinical consequence of CHIP is not well understood, it is linked to an increased risk of primary hematologic malignancies and increased all-cause mortality. A recent study reported a higher prevalence (26%) of CHIP in patients with advanced cancers (Zehir A, ASCO abstract, 2016). However, the prevalence of CHIP in patients developing therapy-related myeloid neoplasms (T-MN) is unknown. We hypothesize that chemotherapy treated cancer patients with CHIP are at higher risk for T-MN development. To address this, we conducted a nested case-control study to compare the prevalence of CHIP in cancer patients who later developed T-MN compared to those that did not. We performed sequential targeted and whole exome sequencing of T-MN cases and described clonal evolution in cases for who paired CHIP and T-MN samples were available.


We identified all patients who consented to our institutional biobanking protocol with a primary cancer preceding T-MN and an age ≥ 70 years at the time of either cancer. Chart reviews were conducted to verify that only patients who received chemotherapy and provided a blood sample before development of T-MN were included. Controls were defined as cancer patients who did not develop a subsequent malignancy and were matched to cases 4:1 on gender, primary tumor diagnosis, age, smoking status (ever/never), chemotherapy drug class, and follow-up time.

DNA was isolated from peripheral blood (CHIP) or bone marrow samples (T-MN), and targeted amplicon based next-generation sequencing was performed to identify somatic mutations in genes associated with CHIP (49 genes, ThunderBolts Myeloid Panel, RainDance). Mesenchymal stem cells and CD3+ cells derived from the T-MN sample were used as independent germline controls to confirm somatic CHIP mutations. Whole exome sequencing was also performed (Agilent SureSelect XT Clinical Research Exome, Illumina NextSeq Sequencer) in paired CHIP and T-MN samples and clonal architecture was inferred using SciClone (Miller CA, PLoS Comput Biol, 2014). CHIP was defined in any sample that harbored a somatic mutation at an allele frequency of >3%.


After screening 105,998 consented individuals from 2006 to 2016, a total of 13 patients (Figure 1a) were identified. The most common primary cancer in patients who developed T-MN was lymphoma, followed by adenocarcinoma (Table 1). The mean time to development of T-MN was 6.1 years and the mean time from the sampling date to the diagnosis of T-MN was 1.8 years. There were no statistical differences in the chemotherapy received by cases and controls (Table 1). The T-MN diagnosis was AML in 6 and MDS in 7 patients, and the majority (10/13) of patients harbored complex cytogenetics. T-MN patients had a poor overall survival (median 11 mo, Figure 1b). The prevalence of CHIP in cases and controls was higher (33%) than reported in individuals without cancer (10%), implying overlapping risk variables. Patients with T-MN had a significantly higher prevalence of CHIP prior to T-MN diagnosis when compared to matched controls (61.5% vs. 26.8%, p=0.02). The most commonly mutated gene in CHIP patients with T-MN was TP53 (36.4% vs. 5.4% in non-T-MN patients, p=0.02), while CHIP patients who did not develop T-MN more commonly harbored mutations in TET2 (35%) (Fig 1c). There was no difference in the mean allele frequencies (MAF) of CHIP mutations in cases vs. controls (9.4% vs. 14.3%, p=0.27). There was also no trend in the number or MAF of CHIP mutations observed and time to T-MN. In the majority of cases (83.3%), CHIP MAF expanded at the time of T-MN, however, a subset of paired samples (16.7%) harbored CHIP mutations that retracted giving way to expansion of a distinct mutant clone (Fig 1d).


Chip often precedes development of T-MN in chemotherapy-treated cancer patients. The distribution of CHIP-related gene mutations differs between individuals with T-MN vs. those without suggesting that there may be mutation-specific differences in T-MN risk. Further, although most CHIP mutations represented the founding leukemic mutation based on allelic frequency, some CHIP mutations retracted at the time of T-MN. These studies support the use of CHIP to inform individualized T-MN risk across cancer.  

Tables and Figures


Disclosures: Lancet: Pfizer: Research Funding; Novartis: Consultancy; Karyopharm: Consultancy; Celgene: Consultancy, Research Funding; Jazz Pharmaceuticals: Consultancy; Boehringer Ingelheim: Consultancy; Baxalta: Consultancy; Janssen: Consultancy. Komrokji: Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Speakers Bureau. Padron: Incyte: Research Funding; CTI: Research Funding; KALOBIOS: Research Funding.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH